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Abstract: Platinum drugs are among the most effective anticancer agents, but their mode of action is
still not fully understood. We therefore carried out a systematic investigation on the cellular activities
of cisplatin, carboplatin and oxaliplatin in A498 kidney cancer cells. Cytotoxicity was higher for
cisplatin and oxaliplatin compared to carboplatin, with induction of apoptosis as the preferred mode
of cell death. Gene expression profiling displayed modulation of genes related to DNA damage
response/repair, cell cycle regulation and apoptosis which was more pronounced upon oxaliplatin
treatment. Furthermore, repression of specific DNA repair genes was restricted to oxaliplatin.
Transcriptional level observations were further analyzed on the functional level. Uptake studies
revealed low intracellular platinum accumulation and DNA platination upon carboplatin treatment.
Removal of overall DNA platination was comparable for the three drugs. However, no processing of
oxaliplatin-induced interstrand crosslinks was observed. Cisplatin and carboplatin influenced cell
cycle distribution comparably, while oxaliplatin had no effect. Altogether, we found a similar mode
of action for cisplatin and carboplatin, while the activity of oxaliplatin appeared to differ. This might
be clinically relevant as due to the difference in mode of action oxaliplatin could be active in tumors
which show resistance towards cisplatin and carboplatin.
Keywords: cisplatin analogues; tumor cells; gene expression profiling; DNA damage response
1. Introduction
Cisplatin is one of the most active chemotherapeutic drugs used for the treatment of various solid
neoplasms, including testicular, bladder, lung and head and neck cancer [1]. However, its clinical
utility is restricted by severe side effects, especially acquired or intrinsic tumor cell resistance and
dose-limiting nephrotoxicity [2]. To overcome these limitations, great efforts have been made to search
for cisplatin analogues which are better tolerated by patients and/or show anticancer activity in cisplatin
resistant tumors. Modification of the structure of cisplatin led to the development of carboplatin and
oxaliplatin (Figure 1) [3]. In various cancer cell lines, carboplatin shows less toxicity than cisplatin at
equimolar concentrations [4]. It is used as first-line treatment of patients with advanced ovarian cancer,
and is also clinically useful for the treatment of a number of other types of cancer, such as advanced
small cell and nonsmall cell lung cancer, while it shows inferior activity than cisplatin in germ cell
tumors and bladder and head and neck cancer [5]. Oxaliplatin has a different pattern of activity to that
of cisplatin, and proved to be active in some tumor cells which are resistant to cisplatin [6]. It is the
latest platinating drug to have been granted worldwide approval, and is used in combination with
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5-fluorouracil for the treatment of metastatic colorectal cancer, which is insensitive to treatment with
cisplatin and carboplatin.
Figure 1. Structures of the clinically approved platinum-based anticancer drugs cisplatin, carboplatin
and oxaliplatin.
Even though cisplatin, carboplatin and oxaliplatin play a major role in tumor therapy, there is
a huge interest in the development of new, more efficient platinum-based antitumor agents which
might broaden the range of treatable tumors and/or be better tolerated by patients [7,8]. To further
develop the field of platinum-based therapy, it is, however, essential to better understand the mode of
action of the established platinum therapeutics, as an understanding of how these therapeutics induce
their antitumor effects would help in the development of new drugs that show activity in tumors
which remain unresponsive to present platinum drugs and exhibit fewer unwanted side effects. Due to
their respective structural characteristics, established platinum-based compounds are supposed to
cause a differing pattern of responses in cells and also in the whole body, but the exact mechanism of
their antitumor activity is still not known. Especially for oxaliplatin, knowledge about the mode of
action is still scarce. There is evidence that platinum compounds mediate their antitumor activity by
damaging DNA [9]. Furthermore, protein platination, which might play a role in the pharmacological
characteristics of platinum compounds, has been reported [10,11]. In the present study, we carried
out a thorough investigation of the mechanisms of action of carboplatin and oxaliplatin in the renal
cell carcinoma cell line A498. The origin of A498 cells is the proximal tubule of a clear cell renal cell
carcinoma, and these cells are widely used in cancer research since they belong to the NCI-60 panel [12].
The proximale tubule is also the site of cisplatin-induced damage and inflammation, which is the
underlying cause of dose-limiting severe nephrotoxicity observed for this drug. The mode of action of
cisplatin was investigated using A498 cells and published previously [13]; data relevant to the current
investigation are included in the present study for comparison. The cellular activity of platinum drugs
was analyzed on the transcriptional level using gene expression analysis, and observations on the
transcriptional level were further examined at the functional level for confirmation. Our results show
that cisplatin and carboplatin share a comparable mode of action, while oxaliplatin has a distinct
pattern of activity.
2. Results
2.1. Cytotoxic Potential of Platinum-Based Compounds
To investigate the toxic potential of platinum-based compounds in tumor cells, A498 kidney
cancer cells were treated with the respective drug for 1 h. Acute toxicity was determined by relative cell
count (RCC) and long-term toxic effects were measured by colony formation ability (CFA) (Figure 2).
Regarding relative cell count (Figure 2A), cisplatin and oxaliplatin showed a similar cytotoxic potential
in A498 cells, represented by an IC50 of 27 µM for cisplatin and 36 µM for oxaliplatin (Table 1).
Carboplatin, on the other hand, showed a comparable effect only at concentrations tenfold higher
than cisplatin (IC50 = 273 µM). Regarding the long-term cytotoxic effects, oxaliplatin was slightly
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less toxic than cisplatin, with an IC50 of 12 µM compared to 6 µM for cisplatin (Figure 2B, Table 1).
However, the standard deviations of both compounds need to be taken into account, since they overlap.
To achieve a similar long-term toxic effect, carboplatin needed to be applied in over tenfold higher
concentrations than cisplatin (Figure 2C, Table 1).
Figure 2. Cytotoxicity of platinum compounds in A498 cells. (A): Relative cell count (RCC) after
treatment with cisplatin, carboplatin or oxaliplatin. A498 cells were incubated for 1 h with cisplatin
(10, 20, 40, 80 µM), carboplatin (80, 160, 320, 500 µM) or oxaliplatin (20, 40, 80, 160 µM). After 72 h
postcultivation, cell count was determined. RCC was obtained by normalization to the untreated
control. The mean values are shown of three independent experiments ± standard deviation. (B)/(C):
Colony formation ability (CFA) of A498 cells after treatment with (B) cisplatin or oxaliplatin or (C)
carboplatin. Cells were incubated for 1 h with cisplatin (5, 10, 15, 20 µM), oxaliplatin (5, 10, 15, 20 µM)
or carboplatin (50, 100, 150, 200 µM). Afterwards, cells were cultivated for 12 days for colony formation.
Colonies were counted and the treated samples were normalized to the untreated control. The mean
values are shown of three independent experiments ± standard deviation.
Table 1. IC50 values of cisplatin, carboplatin and oxaliplatin determined in A498 cells by relative cell
count (RCC) and colony formation ability (CFA).
Platinum-Based Compound RCC [µM] CFA [µM]
cisplatin 27 ± 4.1 6 ± 3.4
carboplatin 273 ± 6.9 153 ± 6.1
oxaliplatin 36 ± 5.8 12 ± 2.0
2.2. Intracellular Accumulation and DNA Platination
To investigate intracellular platinum accumulation, A498 cells were treated for 2 h with 50 µM
of the respective compound, and the intracellular platinum amount was measured by AAS (Table 2).
Cisplatin treatment resulted in an intracellular accumulation of 23 ng Pt/106 cells, while oxaliplatin
treatment led to 14.9 ng Pt/106 cells. For carboplatin, 4.8 ng Pt/106 cells were observed when cells were
treated with 50 µM of the drug, while incubation with 300 µM carboplatin showed with 25 ng Pt/106
cells a similar intracellular platinum level as cisplatin. As DNA is the primary target of activity for
platinum-based compounds, DNA platination was measured by ICP-MS in A498 cells treated with
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50 µM of the respective compound. The amount of platinum bound to DNA directly after a 2 h
exposure is shown in Table 2. DNA platinum binding was associated with intracellular platinum levels,
with high amounts of overall DNA platination measured for cisplatin (383.5 nmol Pt/g DNA) and
oxaliplatin (149.5 nmol Pt/g DNA), while the amount of DNA platination following treatment with
carboplatin was low, i.e., 17 nmol Pt/g DNA.
Table 2. Platinum accumulation and DNA platination in A498 cells following incubation for 2 h
with 50 µM of the platinum-based compound. The mean values are shown from three independent
determinations ± standard deviation (* two independent determinations). The result of cisplatin





0 h 24 h
cisplatin 23 ± 4.6 383 ± 252.2 149.5 ± 76.6
carboplatin 4.8 ± 0.2 17.0 ± 12.7 * 6.5 ± 0.7 *
oxaliplatin 14.9 ± 1.0 149.5 ± 76.6 36 ± 5.5
2.3. Gene Expression Analysis
The impact of carboplatin and oxaliplatin on the gene expression profiles of genes related to
genomic stability was investigated in A498 cells using high-throughput RT-qPCR [14]. The results are
summarized in a heatmap in Figure 3 and compared to gene expression profiles already established for
cisplatin [13]. Relative gene expressions were calculated by normalizing the treated samples to the
untreated control, and are expressed as log2 values. A change of ±1 in gene expression compared to
the untreated control was considered a relevant effect, but concentration-dependent trends were also
considered. Carboplatin led to a gene expression pattern comparable to that of cisplatin. Oxaliplatin also
increased the transcript levels of genes modulated by cisplatin. The three platinum compounds caused
a concentration-dependent induction of the transcription factor MDM2 gene, the DNA damage
response genes GADD45A and RRM2B, the nucleotide excision repair genes DDB2 and XPC, the cell
proliferation-associated genes CDKN1A, PLK3 and PPM1D and the apoptosis-associated genes APAF1,
BBC3, PMAIP1 and TNFRSF10B, indicating activation of the respective pathways. The impact on these
cellular control systems was most pronounced after treatment with oxaliplatin, while cisplatin and
carboplatin enhanced the transcript levels of the described genes to a similar extent. With regard to
specific DNA repair genes, however, a different impact on expression was observed upon treatment with
the respective platinum drug. While homologous recombination-associated genes BRCA1, BRCA2 and
RAD51, the mismatch repair gene MSH2 and PARP1 which is involved in single and double strand
break repair, were repressed by oxaliplatin in a concentration-dependent manner, almost no modulation
of these genes was observed for cisplatin and carboplatin. Oxaliplatin also drastically decreased the
expression of E2F1 gene coding for the transcription factor E2F1 which regulates the expression of
genes involved in numerous cellular functions, including DNA repair.
With regard to oxidative stress response, the platinum compounds had little impact on gene
expression (Figure S1). Solely GPX2 coding for glutathione peroxidase was induced by cisplatin.
When analyzing the inflammation marker gene IL-8, a concentration-dependent increase was observed,
with the highest levels of IL-8 transcript seen with oxaliplatin treatment (Figure 4). Compared to
oxaliplatin, cisplatin and carboplatin showed a moderate impact on IL-8 expression which reached a
relevant level with the highest drug concentration used.
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Figure 3. Gene expression profiling of A498 cells after treatment with cisplatin, carboplatin or oxaliplatin.
Cells were treated for 1 h with various concentrations of cisplatin (10, 20, 50 µM), carboplatin (50,
100, 200, 300, 400, 500 µM) or oxaliplatin (20, 50, 100, 150 µM) followed by a postcultivation of 24 h.
Gene expression was determined by high-throughput RT-qPCR. Genes were grouped into the clusters
transcription factors, DNA damage response and repair, cell cycle and proliferation and apoptosis.
The log2 mean values are shown for three independent experiments normalized to the untreated control
whereby the control equals 0. The data of cisplatin-induced gene expression are taken from [8].
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Figure 4. Gene expression of IL-8 in A498 cells after incubation with cisplatin, carboplatin or oxaliplatin.
Cells were treated for 1 h with cisplatin (10, 20, 50 µM), carboplatin (50, 100, 200, 300, 400, 500 µM) or
oxaliplatin (20, 50, 100, 150 µM), followed by a postcultivation of 24 h. Afterwards, gene expression
was analyzed using high-throughput RT qPCR. The log2 mean values are shown of three independent
experiments normalized to the untreated control whereby the control equals 0 ± standard deviation.
The data for cisplatin are taken from [8].
2.4. Impact of Platinum Drugs on p53 Levels
Gene expression analysis revealed that the platinum drugs led to an increased expression of
MDM2, XPC, DDB2, GADD45A, RRM2B, CDKN1A, PLK3, PPM1D, APAF1, BBC3, PMAIP1 and
TNFRSF10B. These genes are all target genes of the tumor suppressor p53 [15]. As an increased
expression of p53 target genes is an indication of the activation of p53, p53 protein levels in cells treated
with carboplatin or oxaliplatin were analyzed by immunoblotting and compared to findings previously
described for cisplatin [13]. Incubation with carboplatin or oxaliplatin led to a concentration-dependent
increase in p53 protein levels which was most pronounced for oxaliplatin, while carboplatin increased
p53 levels comparably to cisplatin (Figure 5A,B).
2.5. DNA Damage Response and DNA Repair
Gene expression profiling displayed increased levels of DDB1, DDB2, XPC, GADD45A and
RRM2B, indicating the activation of the DNA damage response and repair system by the platinum
drugs. We therefore investigated the repair of platinum-induced DNA damage on a functional level.
Cells were treated with the respective drug for 2 h and ICP-MS was used to measure platinum
bound to DNA directly after drug exposure and after a recovery period of 24 h. The amount of
overall DNA platination was reduced to less than 40% within 24 h in case of damage induced by
cisplatin and carboplatin, and to less than 30% for oxaliplatin-induced damage, indicating the ability
for repair of DNA platinum lesions (Table 2). DNA damage induced by cisplatin, carboplatin and
oxaliplatin consists to over 90% of intrastrand crosslinks between GG or GA [16]. However, a small
percentage of interstrand crosslinks (ICLs) is also formed in response to treatment with the platinum
drugs. As phosphorylation of H2AX can be used as a marker for the generation and processing of
DNA ICLs [17,18], we measured overall fluorescence staining for γ-H2AX formation upon treatment
with the respective platinum drug. Overall, γ-H2AX fluorescence measurement was applied, since
cisplatin-induced foci are small and difficult to count accurately. γ-H2AX fluorescence were observed
24 h post-treatment with cisplatin and carboplatin and increased over time, while no fluorescence signal
beyond background was detected following treatment of A498 cells with oxaliplatin (Figure 6A,B).
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Figure 5. Analysis of the protein level of p53 in A498 cells after incubation with cisplatin, carboplatin
or oxaliplatin. Cells were treated for 1 h with cisplatin (10, 20, 50 µM), carboplatin (50,100, 200, 300, 400,
500 µM) or oxaliplatin (10, 20, 50, 100, 150 µM). After a 24 h postcultivation period, the protein level of
p53 was determined by immunoblot. (A): Examples of a representative immunoblot of each compound.
ERK2 was used as a loading control (B): Semiquantification of the immunoblots. Including the loading
control, the treated samples were normalized to the untreated control. With the exception of treatment
with 50 µM carboplatin or 150 µM oxaliplatin, all concentrations were analyzed in three independent
experiments; the results are shown as mean values ± standard deviation. N.B. 50 µM carboplatin or
150 µM oxaliplatin were analyzed only once, as no changes were seen after 50 µM carboplatin incubation
or extremely high levels of p53 regarding the incubation with oxaliplatin. Results of cisplatin-induced
p53 levels are taken from [8].
2.6. Cell Cycle Regulation and Apoptosis
Induction of the cell cycle related genes CDKN1A, CCND1, PLK3 and PPMID and the apoptosis
related genes BBC3, APAF1, PMAIP1 and TNFRSF10B suggested modulation of the respective pathway
by the platinum drugs. DAPI staining and flow cytometry was therefore used for functional analysis
of cell cycle regulation and apoptosis upon treatment with carboplatin and oxaliplatin, and the results
were compared to data established for cisplatin [13]. A498 cells were treated with the respective
compound for 1 h and cell cycle distribution was measured after a 24, 48, 72 and 96 h recovery period.
Two different concentrations were chosen for carboplatin (200, 500 µM) and oxaliplatin (20, 50 µM).
Cisplatin we used solely at a concentration of 50 µM, as cell cycle distribution upon cisplatin treatment
has been described previously numerous times [19,20]. When used in equitoxic concentrations,
carboplatin affected cell cycle distribution of A498 cells comparably to cisplatin (Figure 7). Treatment of
the cells with carboplatin (500 µM) caused a S phase arrest after 24 h postcultivation, which was
followed by a G2/M arrest after 48 h. The percentage of cells in the three different phases of the cell
cycle then further declined until 96 h, while the percentage of cells in the subG1 phase increased.
Cell cycle distribution was essentially the same after incubation of the cells with 50 µM cisplatin.
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Additionally, 200 µM carboplatin resulted in only a slight increase of the S phase as well as the G2/M
phase after 24 h postcultivation. After 72 h postcultivation, no differences in the cell cycle distribution
of the untreated control and the treated cells were observed. This might be explained by the low DNA
platination levels observed upon carboplatin treatment due to its slower reaction kinetics compared to
cisplatin, in addition to lower platinum accumulation (Table 2). In contrast to cisplatin and carboplatin,
oxaliplatin did not show any substantial effect on cell cycle control and regulation. Incubation with
20 µM oxaliplatin caused a slight increase in the G0/G1 phase at the expense of cells in the G2/M phase.
However, no further changes between the untreated control and the treated cells were observed up to
96 h post-treatment. Incubation with 50 µM oxaliplatin led to a slight decrease of the S phase after 24 h,
while the percentages of cells in the other phases were slightly increased. The small increase of cells in
the G2/M phase persisted until 96 h.
Figure 6. Analysis of γ-H2AX after incubation of A498 cells with cisplatin, carboplatin or oxaliplatin.
Cells were treated with cisplatin or oxaliplatin (20, 50 µM) or carboplatin (200, 500 µM), followed by
postcultivation of 24, 48 or 72 h. γ H2AX fluorescence was measured using fluorescence microscopy.
(A): Representative microscope pictures of A498 cells treated with the platinum-based compounds at
the highest concentration. (B): Quantification of the fluorescence signal. Overall γ-H2AX fluorescence
was evaluated and values were normalized to the untreated control. The mean values are shown of
three independent experiments ± standard deviation.
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Figure 7. Analysis of the cell cycle distribution of A498 cell after treatment with cisplatin, carboplatin or
oxaliplatin. Cells were incubated for 1 h with cisplatin (50 µM), carboplatin (200, 500 µM) or oxaliplatin
(20, 50 µM) followed by postcultivation of 24, 48, 72 or 96 h. Cell cycle distribution was analyzed
by DAPI (4′,6′-diamidino-2-phenylindole) staining via flow cytometry. The mean values are shown
of three independent experiments of the percentage distribution of the cell cycle phases ± standard
deviation. The data for cisplatin are taken from [8].
To analyze the induction of apoptosis on a functional level and to distinguish between apoptotic
and necrotic cell death, cells were stained with annexin V-FITC and PI and fluorescence was measured
by flow cytometry. A498 cells were incubated with carboplatin or oxaliplatin for 1 h followed by
postcultivation for 24, 48, 72 and 96 h. The results were compared to cisplatin (Figure 8). All three
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platinum compounds caused the induction of apoptosis as the preferred mechanism of cell death.
Following treatment with 50 µM cisplatin, the percentage of apoptotic cells increased after just 24 h
postcultivation and continued up to 48 h, while the percentage of necrotic and late-apoptotic cells also
increased. The level of dead cells in general remained the same at 72 h and 96 h, but the percentage
of necrotic and late-apoptotic cells increased, whereas the percentage of apoptotic cells declined.
The treatment of A498 cells with 200 µM carboplatin also led to an increase of apoptotic cells after
24 h postcultivation. However, after 96 h, the percentage of dead cells drastically declined, while the
percentage of vital cells increased from 50 % to 80 %. Under these conditions, the cells probably repaired
DNA damage and recovered. Nevertheless, the percentage of dead cells in general also declined
after incubation with 500 µM carboplatin, but not as drastically as seen with 200 µM. Oxaliplatin also
caused an increase in the percentage of apoptotic cells after 24 h postcultivation at both concentrations.
After 96 h postcultivation, the treatment with 20 µM oxaliplatin led to a slight decline in the percentage
of dead cells. This was not seen with an incubation of 50 µM oxaliplatin. Compared to carboplatin and
oxaliplatin, cisplatin caused the highest percentage of necrotic cells.
Figure 8. Analysis of apoptotic and necrotic cells after incubation of A498 cells with cisplatin,
carboplatin or oxaliplatin. Cells were incubated for 1 h with cisplatin (50 µM), carboplatin (200, 500 µM)
or oxaliplatin (20, 50 µM) followed by postcultivation of 24, 48, 72 or 96 h. To distinguish between
apoptotic and necrotic + late apoptotic cells, cells were stained with Annexin V-FITC and propidium
iodide (PI). Cell cycle distribution was then analyzed by flow cytometry. The mean values are shown
of three independent experiments ± standard deviation. The data for cisplatin are taken from [8].
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3. Discussion
The platinum drugs cisplatin, carboplatin and oxaliplatin are widely used for cancer treatment,
but the molecular mechanisms that mediate their anticancer activity are not fully elucidated.
In particular, limited information is available regarding the mode of action of oxaliplatin. In the
present study, the mechanistic activity of carboplatin and oxaliplatin was investigated in the A498
kidney cancer cell line and compared to observations for cisplatin [13]. The main outcome of our
investigation was the finding that cisplatin and carboplatin share the same mechanism of activity,
but oxaliplatin differs in its mode of action. The three platinum compounds were cytotoxic to A498 cells,
with a stronger toxicity observed for cisplatin and oxaliplatin compared to carboplatin at equimolar
concentrations. The lower toxicity of carboplatin compared to cisplatin has also been reported in
previous studies in various cancer cells lines. It has been noted that carboplatin is less reactive than
cisplatin, as it shows slower reaction kinetics regarding the aquation step. The chelate-leaving group
of carboplatin is considerably more stable than the chloride groups of cisplatin, resulting in slower
aquation and, hence, lower reactivity, yielding an approximately 10-fold slower rate of DNA adduct
formation [21–23]. ICP-MS measurements confirmed lower levels of DNA platination in A498 cells
upon treatment with carboplatin versus cisplatin. Oxaliplatin treatment also resulted in fewer DNA
platination lesions compared to cisplatin, but exhibited a similar cytotoxic activity. This might be
explained by observations that oxaliplatin-induced lesions are generally more cytotoxic than cisplatin
lesions and show a greater inhibition of DNA synthesis [24]. Furthermore, DNA platination was also
associated with intracellular platinum accumulation, with considerably lower platinum accumulation
measured upon carboplatin treatment. Platinum-based compounds enter the cells via passive diffusion
and by active transport via membrane transporters. Copper transporter 1 (Ctr1) and organic cation
transporter 2 (OCT2) have been implicated in the active uptake of platinum-based compounds.
The differences in intracellular accumulation might therefore be explained with the different affinities
of the platinum compounds to these membrane transporters. Regarding Ctr1, cisplatin was found to
have a higher affinity towards the transporter than carboplatin, while oxaliplatin appears to be taken
up by Ctr1 only at low concentrations, whereas uptake at higher concentrations was independent
of Ctr1 [25,26]. With regard to OCT2, various studies suggested a role of OCT2 in the uptake of
cisplatin and oxaliplatin, but not of carboplatin [27,28]. OCT2 is primarily expressed in the kidney,
which might explain low intracellular platinum accumulation following carboplatin treatment of A498
kidney cancer cells and higher levels of accumulation upon treatment with cisplatin or oxaliplatin.
However, intracellular accumulation of platinum not only depends on uptake transporters, but also on
efflux transporters. Two important efflux transporters which are especially expressed in the kidney are
MATE1 and MATE2-K. It could be shown that oxaliplatin represented a substrate for both transporters,
whereas cisplatin was not transported by MATE2-K and at reduced levels by MATE1 [28,29]. Therefore,
varied affinities of the platinum drugs to the efflux transporters might explain the observed differences
in the intracellular accumulation of cisplatin and oxaliplatin.
Systematic gene expression profiling showed a dose-dependent impact of the platinum compounds
on genes related to genomic stability. The repair-related genes GADD45A, XPC, DDB1, DDB2 and
RRM2B were upregulated in response to the compounds; the strongest effect was observed for
oxaliplatin. The modulation of genes related to DNA repair suggests activation of the cellular DNA repair
machinery. ICP-MS was applied to monitor DNA repair at the functional level. Considering whole
DNA platination, ICP-MS measurements revealed reduced amounts of platinum bound to DNA
after a repair period of 24 h, confirming repair of the overall DNA platination damage induced by
the respective platinum compound. Platinum compounds induce various kinds of DNA lesions,
particularly intrastrand crosslinks between two adjacent guanine or two guanine-adenine bases which
make up more than 90% of the induced lesions [30–32]. Cisplatin-induced intrastrand crosslinks
are mainly removed by NER, the main DNA repair pathway dealing with bulky helix-distorting
lesions [33,34]. As the same intrastrand crosslinks are formed by carboplatin, NER consequently also
participates in the repair of carboplatin-induced DNA damage. It was also shown that cisplatin- and
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oxaliplatin-induced DNA lesions are repaired with similar kinetics by the NER system [35]. Indicative of
the activation of NER, transcript levels of XPC, DDB1, DDB2 and GADD45A, which directly or indirectly
take part in NER [36,37], were upregulated by cisplatin, carboplatin and oxaliplatin in the present
study. In addition to intrastrand crosslinks, a small percentage of interstrand crosslinks (ICLs) is
induced by the platinum drugs [30,38]. To monitor the repair of platinum-induced ICLs, γ-H2AX
formation was used as a marker associated with ICL repair [17]. We observed staining for γH2AX
in response to cisplatin and carboplatin, but not oxaliplatin in A498 cells. In agreement with our
observations, no staining for γ-H2AX was observed in lymphoma cells or colon cancer cells after
treatment with oxaliplatin, whereas cisplatin treatment resulted in γ-H2AX foci [39,40]. On the
other hand, γ-H2AX foci were detected in oxaliplatin-treated Chinese hamster ovary cells; the level,
however, was small compared to that of cisplatin-treated cells [41]. As γ-H2AX formation serves
as a marker associated with the induction and processing of ICLs [17], the lack of formation of
γ-H2AX upon oxaliplatin treatment might suggest that either oxaliplatin does not induce ICLs or
oxaliplatin-induced ICLs are not repaired. However, an induction of ICLs by oxaliplatin was reported
by Woynarowski and colleagues who studied oxaliplatin-induced DNA damage in naked and cellular
DNA. They observed that even though oxaliplatin, in general, induced less DNA platination damage
compared to cisplatin, with mainly DNA intrastrand crosslinks being formed, few DNA interstrand
crosslinks were nonetheless observed [42]. One might speculate that oxaliplatin-induced ICLS are less
efficiently repaired by the cellular machinery. Structural differences between ICLs induced by cisplatin
versus oxaliplatin have been reported [38]. The bulky DACH ligand of oxaliplatin sticks out of the
helix and leads to a different bending of the DNA; as a result, oxaliplatin-induced ICLs might be poorly
recognized or even prevented from binding by some DNA repair enzymes [32,43]. ICLs are removed
by ICL repair, a process which is less well understood than NER [44]. In mammalian cells, NER and
homologous recombination take part in ICL repair, although additional pathways involving DNA
polymerases may also contribute to this [45]. Biochemical studies implicate the repair proteins BRCA1,
BRCA2, RAD51 in homologous recombination [46]. Decreased transcript levels of BRCA1, BRCA2 and
RAD51, as observed by gene expression profiling, might be an indication of a lack of processing of
oxaliplatin-induced ICLs. Interestingly, despite differences in the amount of DNA platination, as shown
in the present study and by Woynarowski and colleagues [42], oxaliplatin and cisplatin exhibit similar
cytotoxicity. One can speculate that oxaliplatin exerts its cytotoxic activity not only through DNA
platination, but also additional mechanisms. Bruno and colleagues suggest that ribosome biogenesis
stress might be the key player in the mode of action of oxaliplatin [39]. Ribosome biogenesis stress can
lead to a profound activation of p53 which, in turn, induces cell death [47]. This might also explain why
the protein level of p53 was more increased after treatment with oxaliplatin than cisplatin or carboplatin
(Figure 5). Elevated p53 protein levels upon drug treatment also suggest activation of p53, which was
confirmed by increased transcript levels of p53 target genes MDM2, XPC, DDB2, GADD45A, RRM2B,
CDKN1A, PLK3, PPM1D, APAF1, BBC3, PMAIP1 and TNFRSF10B [15]. The involvement of p53 in
the mode of action of platinum drugs has been reported (Köberle, unpublished observations) [48,49].
However, it has also been reported that platinum drugs can induce cell death in the absence of
functioning p53 [13,50]. In our study, p53 appeared to play a role in the mode of action of all three
platinum-based compounds, as shown by increased expression of p53 target genes and p53 protein
stabilization. A498 cells harbor wild type p53, which might suggest that in cell lines with functioning
p53, platinum-based drugs will use a p53-dependent DNA damage response.
As reactive oxygen species (ROS) and inflammation are often the cause of unwanted side effects
of chemotherapeutic drugs [51], the impact of cisplatin, carboplatin and oxaliplatin on inflammatory
and oxidative stress response has been investigated. Gene expression analysis revealed that the three
platinum drugs had only little impact on genes associated with oxidative stress response. Studies on
the functional level regarding the induction of ROS or oxidative DNA damage also did not show any
unambiguous results. The lack of an oxidative stress response, therefore, does not implicate ROS as major
determinants of platinum-induced side effects For the clinically approved platinum drugs, severe side
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effects are reported. The dose-limiting side effect of cisplatin is nephrotoxicity, while carboplatin
induces severe myelosuppression, and neurotoxicity is caused by oxaliplatin. Inflammation mediated
by chemokines such as IL-8 is thought to play a key role in cisplatin-induced nephrotoxicity [52–54].
An inflammatory response in oxaliplatin-induced neuropathies is still questionable [55], but IL-8 seems
to play a role in the mode of action of oxaliplatin [56]. The inflammation marker IL-8, which was
dose-dependently upregulated by the platinum compounds, is transcriptionally controlled by
NF-κB [57]. During inflammatory processes a correlation between the expression of NFκB, IL-8 and
VEGFA, which belongs to the vascular endothelial growth factor family (VEGF), was observed [58].
In our gene expression analysis, both cisplatin and oxaliplatin caused a concentration-dependent
increase in the NF-κB gene NFKB2 and in VEGFA, while carboplatin did not show any modulation
of NFKB2 and VEGFA. One might therefore speculate that cisplatin as well as oxaliplatin cause an
inflammatory response in A498 cells, while carboplatin does not. However, further studies need to
substantiate this.
With respect to genes associated with cell cycle regulation, increased transcript levels of CDKN1A,
PLK3 and PPM1D, all of which indicative of cell cycle arrest [59–61], were observed in response to
cisplatin, carboplatin or oxaliplatin. In addition, oxaliplatin also upregulated SIRT2, which also serves
as indication of cell cycle arrest [62]. On the other hand, oxaliplatin also enhanced the expression of
CCND1 and EGFR, indicating cell cycle progression rather than cell cycle arrest [63]. Most strikingly,
oxaliplatin led to a pronounced repression of E2F1. E2F1 serves as a transcription factor which is
involved in cell cycle regulation. It appears to be essential for the entry into S phase [64]. Kiyonari and
colleagues also detected a downregulation of E2F1 after the treatment of colon cancer cell lines HCT116
and LoVo with oxaliplatin [48]. As the downregulation of E2F1 was associated with a decreased
expression of enzymes involved in thymidylate synthase, they suggest that these observations might
explain the synergistic effect of oxaliplatin and 5-fluorouracil (5-FU) in the treatment of advanced
colon carcinoma [48]. In accordance with the upregulation of CDKN1A, PLK3 and PPM1D, cell cycle
arrest was observed upon treatment with cisplatin and carboplatin at the functional level, which is in
agreement with published data [65]. Oxaliplatin, on the other hand, showed no substantial impact on
cell cycle distribution in A498 cells kidney cancer cells. For colon cancer cells, only a weak effect of
oxaliplatin on the cell cycle was reported [20]. Furthermore, a possible effect of oxaliplatin on cell cycle
distribution might be cell type specific [66]. Nevertheless, in our studies using a kidney cancer cell
line, we did not observe a substantial impact by oxaliplatin on the cell cycle, whereas cisplatin and
carboplatin induced significant change in the cell cycle distribution.
Treatment of A498 cells with the three platinum complexes modulated genes related to apoptosis.
Induction of the pro-apoptotic genes APAF1, BBC3, PMAIP1 and TNFRSF10B was observed upon
treatment with cisplatin and oxaliplatin, indicating apoptotic signaling via the intrinsic and extrinsic
cascade. Regarding carboplatin, APAF1, BBC3 and PMAIP1 were upregulated, while the transcript
level of TNFRSF10B was not affected, suggesting induction of apoptosis via the intrinsic cascade cy
carboplatin. Accordingly, for the platinum compounds, induction of apoptosis was confirmed by
flow cytometry on the functional level, in agreement with previous investigations in various cancer
cells [67–69]. Flow cytometry also revealed induction of necrosis, especially in the case of cisplatin,
but apoptosis appeared to be the primary mechanism of cell death.
4. Materials and Methods
4.1. Figures, Platinum-Based Chemotherapeutics
Cisplatin solution was provided by the Municipal Clinic Karlsruhe with a concentration of 1 g/L.
Carboplatin and oxaliplatin solutions were purchased from Accord Healthcare Limited (Middlesex,
Great Britain) at concentrations of 10 mg/mL and 5 mg/mL, respectively.
Int. J. Mol. Sci. 2020, 21, 6928 14 of 21
4.2. Cell Culture
The studies were performed using the renal cell carcinoma cell line A498 [70] which was purchased
from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). A498 cells were cultivated
as monolayers in RPMI-1640 medium supplemented with 10% fetal calf serum, penicillin (100 U/mL) and
streptomycin (100 µg/mL) (Sigma Aldrich, Steinheim, Germany) at 37 ◦C in a humidified atmosphere
of 5% CO2.
4.3. Cytotoxicity Studies
A relative cell count was performed by seeding 2.5 × 105 cells in duplicate in 6 cm dishes.
After cultivation for 24 h, cells were treated for 1 h with cisplatin (10, 20, 40 and 80 µM), carboplatin
(40, 80, 160, 320 and 500 µM) or oxaliplatin (20, 40, 80 and 160 µM) followed by postincubation
for 72 h. Subsequently, cell count was undertaken using a CASY® cell counter (CASY® TTC
Cell Counter & Analyzer System). Relative cell count was performed by normalizing the cell
count of surviving cells from the treated samples to the untreated control expressed as percentage.
For the determination of colony formation ability, 600 cells were seeded in triplicates in 6 cm dishes.
After cultivation for 24 h, cells were incubated with carboplatin (50, 100, 150 and 200 µM) or oxaliplatin
(5, 10, 15 and 20µM) for 1 h and cultivated for 11–12 days in fresh medium. Colonies were fixed for 5 min
with ice cold 96% ethanol, stained with 5% Giemsa (Roth, Karlsruhe Germany) and those consisting
of 50 or more cells were counted. Colony formation in treated dishes was expressed as a percentage
of colony formation in the untreated controls. RCC and CFA were performed in three independent
experiments. CFA data for cisplatin (5, 10, 15 and 20 µM) were previously described in [13].
4.4. Intracellular Platinum Accumulation
Intracellular platinum accumulation was analyzed via atomic absorption spectroscopy (AAS).
First, 2 × 106 cells were seeded in 10 cm dishes und cultivated for 24 h. In contrast to previous assays,
cells were subsequently treated for 2 h with 50 µM platinum-based compound. A 2-h incubation
time was chosen due to the limits of platinum detection observed for AAS. The total cell count was
measured and cells were pelleted. The cell pellets were digested with a solution of 30% H2O2 and
65% HNO3 (1:1 (v:v)) (Roth, Karlsruhe, Germany) and evaporated. After digestion, the residue was
dissolved in 0.2% HNO3 and used to measure the platinum amount with a PinAAcle 900 T (Perkin
Elmer, Waltham, MA, USA). Platinum was determined at a wavelength of 265.94 nm in a graphite
furnace. The furnace temperature program consisted of two drying stages of 120 ◦C for 30 s and 140 ◦C
for 45 s, a pyrolysis stage of 1300 ◦C for 20 s and an atomization step at 2400 ◦C for 5 s, as well as a
heating step of 2500 ◦C for 5 s. Intracellular platinum accumulation was calculated as Pt ng/106 cells,
and was performed in three independent analyses. The data of platinum accumulation measured after
cisplatin treatment were taken from [13].
4.5. DNA Platination
Due to the limits of detection of platinum by AAS, DNA platination was analyzed by inductively
coupled plasma mass spectroscopy (ICP-MS). First, 3 × 106 cells were seeded in 20 cm dishes and
cultivated for 24 h, followed by incubation with 50 µM platinum-based chemotherapeutic agent for 2 h.
Cells were then harvested either immediately via centrifugation or after a 24 h postincubation period.
Each sample was seeded in duplicate but was combined after DNA extraction to ensure the presence of
enough DNA material for measurements above the determination limit of the ICP-MS, particularly for
measurement of carboplatin and oxaliplatin DNA platination. DNA was extracted by suspending the
pellets in 100 µL warm (37 ◦C) TE-Buffer containing 10 mM Tris-HCl (pH 8.0) and 6.25 mM EDTA (Roth,
Karlsruhe, Germany). This solution was mixed with 900 µL warm (37 ◦C) extraction buffer (pH 8.0)
consisting of 0.01 M Tris, 0.1 M EDTA, (Roth, Karlsruhe, Germany) 0.5% SDS (AppliChem, Darmstadt,
Germany) and 20 µg/mL heat inactivated RNase A (Roth, Karlsruhe, Germany). The samples were
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incubated under agitation at 37 ◦C for 1 h 15 min, followed by supplementation with proteinase K
(20 µg/mL) (Merck Millipore, Darmstadt, Germany) and incubation for another 3 h under agitation
at 50 ◦C. After phenol/chloroform/isoamyl alcohol (25:24:1) extraction (2×) and chloroform/isoamyl
alcohol (24:1) extraction, DNA was precipitated with 1/20 volume sodium acetate (10 M) and 2 volume
ethanol (absolute), washed four times with ethanol (70%), dried and dissolved in 500 µL bidestilled
water for quantification. DNA quantification was performed in duplicate with a NanoQuant plate at a
Tecan Infinite M200 Pro in UV range and checked for purity. Afterwards, samples were evaporated
and digested with nitric H2O2. The residue was dissolved in 2 mL 0.2% HNO3 and used for analysis
with ICP-MS. Platinum amount was analyzed with a Thermo Scientific XSERIES 2 with CCT (collision
cell technology) and a plasma performance of 1400 W. The most frequently isotopes of platinum (194Pt
and 195Pt) were analyzed and the mean of both determinations was calculated. The amount of DNA
platination was calculated in nmol Pt/g DNA and determined in three independent experiments.
4.6. Gene Expression Profiling by High-Throughput RT-qPCR
For gene expression profiling, 1 × 106 cells were seeded in 10 cm dishes and cultivated for 24 h.
An untreated control was included and samples were seeded in duplicate. After cultivation, cells were
treated for 1 h carboplatin (50, 100, 200, 300, 400 and 500 µM) or oxaliplatin (20, 50, 100, and 150 µM)
followed by 24 h postcultivation and cell harvesting via centrifugation. To generate gene expression
profiles, a high-throughput RT-qPCR was performed after RNA isolation using a Fluidigm dynamic
array on a BioMark™ system. Experiments and evaluation were performed according to [14]. The gene
expression profiles of cisplatin treatment (10, 20 and 50 µM) were taken from [13].
4.7. Immunblotting of p53
To determine the p53 protein levels, 1 × 106 cells were seeded in 10 cm dishes and cultivated
for 24 h. Cells were incubated for 1 h with carboplatin (50, 100, 200, 300, 400, 500 µM) or oxaliplatin
(10, 20, 50, 100, 150 µM). After treatment, cells were cultivated for an additional 24 h and harvested
via centrifugation. Protein extraction was carried out by lysing the cell pellets in 120 µL lysis buffer
containing 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 1 mM EDTA, 0.1% Triton X-100 (Roth, Karlsruhe,
Germany) and 1× protease inhibitor (cOmplete Mini, Roche, Mannheim, Germany) for 30 min on ice
under agitation, followed by centrifugation for 20 min at 4 ◦C and 14,000 rpm. The supernatant was
recovered and the protein concentration was analyzed by the Bradford method (Bio-Rad Protein Assay,
Munich, Germany).
For SDS-PAGE, 50 µg protein extract of each sample was used and separated in 10% gel.
Protein transfer was carried out overnight at 4 ◦C on an Amersham Hybond P PVDF membrane
(GE Healthcare, Buckinghamshire, UK) in Tris-glycine buffer (25 mM Tris-HCl, 192 mM glycine,
20% methanol). Unspecific protein binding sites were blocked by incubating the membrane for 1 h
in PBST (Tween 0.005%) with 5% milk powder. Membranes were incubated with 1/2000 diluted
monoclonal p53 antibody (clone DO-7, DAKO, CA, USA) in 5% milk powder-PBST-solution overnight
at 4 ◦C. Afterwards, membranes were washed with PBST and incubated with 1/2000 diluted antimouse
IgG-HRP antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in 5% milk powder-PBST-solution
overnight at 4 ◦C. As a loading control ERK2 was chosen. The antibodies used were polyclonal 1/2000
diluted ERK2 (C-14, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 1/2000 antirabbit IgG-HRP
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were treated as previously stated.
Protein visualization was performed by ECL-detection according to the manufacturers protocol using a
LAS-3000 Imaging System (Fuji, Minato, Japan). Semiquantitative evaluation was carried out with the
program Aida Image Analyzer v.3.27. The detection of p53 protein was performed in three independent
experiments. The results for cisplatin (10, 20, 50 µM) were previously described by [13].
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4.8. Analysis of Apoptosis and Cell Cycle Distribution via Flow Cytometry
First, 2 × 105 A498 cells were seeded in duplicate in 6-cm dishes and cultivated for 24 h. Cells were
then treated for 1 h with 200 and 500 µM carboplatin or 20 and 50 µM oxaliplatin, followed by
postcultivation for 24, 48, 72 and 96 h. Besides an untreated control, 24 h incubation with 500 nm
staurosporine was used as a positive control to check for functionality of the method. Untreated and
positive controls were included for each time point. After postcultivation, the media and cells were
transferred into a 15 mL tube and centrifuged at 4 ◦C and 1300 rpm for 4 min. The supernatant was
discarded and the cells were resuspended in 2 mL PBS from which 1 mL was used for the determination
of apoptosis and 1 mL for analysis of cell cycle distribution.
For analysis of the cell cycle distribution, cells were fixed with 3 mL ice cold ethanol, which was
added slowly under constant mixing to avoid clumping. For complete fixation, cells were stored at
−20 ◦C overnight. The fixed cells were then centrifuged at 4 ◦C and 4000 rpm for 5 min, the supernatant
was discarded and cells were washed with 1 mL PBS, followed by centrifugation. Cells were resuspended
in 300 µL DAPI (4′,6′-diamidino-2-phenylindole) staining solution (Partec, Münster, Germany) and
kept on ice for 30 min in the dark. Fluorescence was measured with a BD LRSII Fortessa flow cytometer
(BD, Heidelberg, Germany) with a violet laser of 488 nm excitation and a bandpass filter of 450/50 nm.
To determine the cell cycle distribution, counts were plotted over the fluorescence signal in a histogram.
For the determination of apoptosis, 1 mL cell suspension was centrifuged, the supernatant
discarded and the cells were resuspended in a mix of 200 µL Ringer solution (147 nM NaCl, 402 nM
KCl, 297 nM CaCl2) + 0.25 µL propidium iodide (PI) (62.5 ng/mL) + 1 µL annexin V-FITC (450 ng/mL)
and kept on ice for 30 min in the dark. While PI was used to determine necrotic/late apoptotic cells,
annexin V-FITC was used to stain apoptotic cells. Fluorescence was again analyzed by flow cytometry
using the same laser as stated above and a bandpass filter of 695/40 nm for the PI signal and of
530/30 nm for the FITC signal. Since the absorption spectra of PI and FITC overlapped, compensation
was required prior to analysis. To distinguish between vital, apoptotic and nectrotic and late apoptotic
cells, the PI signal was plotted in a dot plot over the FITC signal. The determinations of apoptosis and
cell cycle distribution were carried out in three independent experiments. The results for treatment
with 50 µM cisplatin were taken from [13].
4.9. Staining for γ-H2AX
A coverslip was placed in a 3.5 cm Petri dish, and 1 × 105 cells were seeded into the dish and
cultivated for 24 h. Samples were prepared in duplicate. Following 24 h of cultivation, cells were
incubated for 1 h with 20 and 50 µM cisplatin or oxaliplatin, respectively, or 200 and 500 µM carboplatin.
After treatment, cells were postcultivated for 24, 48 or 72 h. At each time point, samples were washed
with PBS and fixed with ice cold 99.9% methanol for 5 min. Methanol was discarded and cells were
again washed with PBS three times for 5 min. Following fixation, cells were permeabilized with a
solution of 0.2% Triton X-100 in PBS for 10 min on a shaker and afterwards washed again with PBS
three times for 5 min. Cells were blocked for 30 min in 1% BSA in PBST solution and then incubated
with 1/1000 diluted mouse monoclonal antiphospho-Histone H2AX (Ser139, clone JBW301, Merck,
Darmstadt, Germany). The coverslips facing the cell side were placed on a droplet containing the
antibody in a wet chamber and incubated for 1 h. After three washing steps with PBS, cells were
incubated with the secondary antibody. A polyclonal antimouse antibody coupled with Alexa Fluor®
488 from Invitrogen (Darmstadt, Germany) diluted 1/1000 in blocking solution was used as a secondary
antibody. Cells were incubated as stated previously for 1 h in the dark and washed again three times.
The coverslips were then placed on a slide with Vectashield HardSet Antifade Mounting Medium
with DAPI (Vector Laboratories, Burlingame, CA, USA) and sealed. Since platinum-induced foci are
small and difficult to count accurately, overall γ-H2AX fluorescence was analyzed by fluorescence
microscopy with a Axio Imager Z2 (Carl Zeiss, Jena, Germany) and the software ZEN. Overall γ-H2AX
fluorescence was evaluated with the software Axio Vision 4.8 and values were normalized to the
untreated control. Studies were performed in three independent experiments.
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5. Conclusions
Our investigation revealed that carboplatin and cisplatin share the same mode of action.
Carboplatin induces identical DNA lesions to cisplatin [23], which lead to a comparable DNA
damage response, as revealed by gene expression profiling and functional analysis in the present study.
The lower toxicity of carboplatin, which was observed in A498 kidney cancer cells and various other
cells including ovarian cancer cells [4], can be explained by lower levels of DNA accumulation and
DNA platination. Lower DNA accumulation is most likely linked to different affinities to the membrane
transporter Ctr1 observed for carboplatin and cisplatin [25]. In addition, a lower aquation rate due
to more stable ligands also contributed to the reduced level of DNA platination upon carboplatin
treatment [21–23]. The mechanism of action of oxaliplatin, however, differed significantly from that
of cisplatin and carboplatin, particularly with respect to induction and processing of DNA damage.
Oxaliplatin exhibited similar cytotoxicity to cisplatin, despite lower levels of DNA platination which
were associated with lower cellular platinum accumulation, possibly due to platinum export via
the membrane transporters MATE1 and MATE2-K [28,29]. It is reported that oxaliplatin-induced
lesions are more cytotoxic than cisplatin lesions and show a greater inhibition of DNA synthesis [24].
Furthermore, oxaliplatin-induced ICLs appear to be less efficiently processed by the cellular machinery,
as we observed using staining for γ-H2AX, which serves as a marker associated with induction and
processing of ICLs [17]. This might be explained by structural differences of ICLs induced by cisplatin
versus oxaliplatin [38]. On the transcriptional level, repression of specific DNA repair genes, especially
related to repair pathways dealing with ICLs, was observed solely for oxaliplatin. Taken together,
a difference in platinum lesions, particularly ICLs, and processing of the ICLs most likely results in a
differing mechanism of action of oxaliplatin compared to cisplatin and carboplatin. This might be of
interest with regard to cisplatin tumor cell resistance. As carboplatin shows cross resistance to cisplatin
due to the same mode of action, oxaliplatin might still be active in tumors which are unresponsive to
cisplatin and carboplatin. Future studies will determine whether the range of platinum-treated tumors
might be expanded by the application of oxaliplatin.
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AAS atomic absorption spectroscopy
CFA colony formation ability
DDR DNA damage response
DSB double strand break
ICL interstrand crosslink
ICP-MS inductively coupled plasma mass spectroscopy
MMR mismatch repair
NER nucleotide excision repair
RCC relative cell count
SSB single strand break
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